248 related articles for article (PubMed ID: 31771194)
1. In-Vivo Gene Therapy with Foamy Virus Vectors.
Rajawat YS; Humbert O; Kiem HP
Viruses; 2019 Nov; 11(12):. PubMed ID: 31771194
[TBL] [Abstract][Full Text] [Related]
2.
Rajawat YS; Humbert O; Cook SM; Radtke S; Pande D; Enstrom M; Wohlfahrt ME; Kiem HP
Hum Gene Ther; 2021 Jan; 32(1-2):113-127. PubMed ID: 32741228
[TBL] [Abstract][Full Text] [Related]
3. Rapid immune reconstitution of SCID-X1 canines after G-CSF/AMD3100 mobilization and in vivo gene therapy.
Humbert O; Chan F; Rajawat YS; Torgerson TR; Burtner CR; Hubbard NW; Humphrys D; Norgaard ZK; O'Donnell P; Adair JE; Trobridge GD; Scharenberg AM; Felsburg PJ; Rawlings DJ; Kiem HP
Blood Adv; 2018 May; 2(9):987-999. PubMed ID: 29720491
[TBL] [Abstract][Full Text] [Related]
4. Intravenous injection of a foamy virus vector to correct canine SCID-X1.
Burtner CR; Beard BC; Kennedy DR; Wohlfahrt ME; Adair JE; Trobridge GD; Scharenberg AM; Torgerson TR; Rawlings DJ; Felsburg PJ; Kiem HP
Blood; 2014 Jun; 123(23):3578-84. PubMed ID: 24642749
[TBL] [Abstract][Full Text] [Related]
5. Foamy virus vectors for gene transfer.
Trobridge GD
Expert Opin Biol Ther; 2009 Nov; 9(11):1427-36. PubMed ID: 19743892
[TBL] [Abstract][Full Text] [Related]
6. Stem cell selection in vivo using foamy vectors cures canine pyruvate kinase deficiency.
Trobridge GD; Beard BC; Wu RA; Ironside C; Malik P; Kiem HP
PLoS One; 2012; 7(9):e45173. PubMed ID: 23028826
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy model of X-linked severe combined immunodeficiency using a modified foamy virus vector.
Horino S; Uchiyama T; So T; Nagashima H; Sun SL; Sato M; Asao A; Haji Y; Sasahara Y; Candotti F; Tsuchiya S; Kure S; Sugamura K; Ishii N
PLoS One; 2013; 8(8):e71594. PubMed ID: 23990961
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Evaluation of Foamy Virus Vector-Mediated Gene Addition in Human Hematopoietic Stem/Progenitor Cells for Correction of Leukocyte Adhesion Deficiency Type 1.
Smith RH; Bloomer H; Fink D; Keyvanfar K; Nasimuzzaman M; Sancheznieto F; Dutta R; Guenther Bui K; Alvarado LJ; Bauer TR; Hickstein DD; Russell DW; Malik P; van der Loo JCM; Highfill SL; Kuhns DB; Pirooznia M; Larochelle A
Hum Gene Ther; 2022 Dec; 33(23-24):1293-1304. PubMed ID: 36094106
[No Abstract] [Full Text] [Related]
9. Foamy Virus Vector Carries a Strong Insulator in Its Long Terminal Repeat Which Reduces Its Genotoxic Potential.
Goodman MA; Arumugam P; Pillis DM; Loberg A; Nasimuzzaman M; Lynn D; van der Loo JCM; Dexheimer PJ; Keddache M; Bauer TR; Hickstein DD; Russell DW; Malik P
J Virol; 2018 Jan; 92(1):. PubMed ID: 29046446
[TBL] [Abstract][Full Text] [Related]
10. Foamy virus vectors: an awaited alternative to gammaretro- and lentiviral vectors.
Rethwilm A
Curr Gene Ther; 2007 Aug; 7(4):261-71. PubMed ID: 17969559
[TBL] [Abstract][Full Text] [Related]
11. Foamy virus vectors.
Mergia A; Heinkelein M
Curr Top Microbiol Immunol; 2003; 277():131-59. PubMed ID: 12908771
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo gene delivery to synovium using foamy viral vectors.
Armbruster N; Weber C; Wictorowicz T; Rethwilm A; Scheller C; Steinert AF
J Gene Med; 2014; 16(7-8):166-78. PubMed ID: 25044583
[TBL] [Abstract][Full Text] [Related]
13. Comparison of three retroviral vector systems for transduction of nonobese diabetic/severe combined immunodeficiency mice repopulating human CD34+ cord blood cells.
Leurs C; Jansen M; Pollok KE; Heinkelein M; Schmidt M; Wissler M; Lindemann D; Von Kalle C; Rethwilm A; Williams DA; Hanenberg H
Hum Gene Ther; 2003 Apr; 14(6):509-19. PubMed ID: 12718762
[TBL] [Abstract][Full Text] [Related]
14. Transduction of umbilical cord blood CD34+ NOD/SCID-repopulating cells by simian foamy virus type 1 (SFV-1) vector.
Zucali JR; Ciccarone T; Kelley V; Park J; Johnson CM; Mergia A
Virology; 2002 Oct; 302(2):229-35. PubMed ID: 12441067
[TBL] [Abstract][Full Text] [Related]
15. Large animal models for foamy virus vector gene therapy.
Trobridge GD; Horn PA; Beard BC; Kiem HP
Viruses; 2012 Dec; 4(12):3572-88. PubMed ID: 23223198
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of foamy viral vector-mediated gene therapy for canine leukocyte adhesion deficiency.
Bauer TR; Tuschong LM; Calvo KR; Shive HR; Burkholder TH; Karlsson EK; West RR; Russell DW; Hickstein DD
Mol Ther; 2013 May; 21(5):964-72. PubMed ID: 23531552
[TBL] [Abstract][Full Text] [Related]
17. Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells.
Zhang F; Thornhill SI; Howe SJ; Ulaganathan M; Schambach A; Sinclair J; Kinnon C; Gaspar HB; Antoniou M; Thrasher AJ
Blood; 2007 Sep; 110(5):1448-57. PubMed ID: 17456723
[TBL] [Abstract][Full Text] [Related]
18. Feline foamy virus-based vectors: advantages of an authentic animal model.
Liu W; Lei J; Liu Y; Lukic DS; Räthe AM; Bao Q; Kehl T; Bleiholder A; Hechler T; Löchelt M
Viruses; 2013 Jul; 5(7):1702-18. PubMed ID: 23857307
[TBL] [Abstract][Full Text] [Related]
19. Unexpected replication pathways of foamy viruses.
Rethwilm A
J Acquir Immune Defic Syndr Hum Retrovirol; 1996; 13 Suppl 1():S248-53. PubMed ID: 8797731
[TBL] [Abstract][Full Text] [Related]
20. Production of foamy virus vector and transduction of hematopoietic cells.
Josephson NC; Russell DW
Cold Spring Harb Protoc; 2010 Sep; 2010(9):pdb.prot5481. PubMed ID: 20810629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
